asciminib hydrochloride
Marketedupdated 2mo agoby $NVS NOVARTIS AG
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for blast phase chronic myelogenous leukemia, bcr-abl1 positive and chronic myelogenous leukemia.
all catalysts(13)
approval · 11
Oct 29, 2021
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Oct 29, 2021
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Oct 12, 2022
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Jun 26, 2023
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Nov 8, 2023
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Jun 18, 2024
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Aug 7, 2024
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Oct 29, 2024
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Oct 29, 2024
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Oct 2, 2025
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Nov 25, 2025
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
phase 0 trial initiation · 1
phase 2 initiation · 1
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that